ENZ

Farmer Bros. Co. Announces Board Refresh and Cooperation Agreement with Stockholders JCP Investment Management and 22NW

Retrieved on: 
Monday, October 31, 2022
Citadel, Tea, Board, Coffee, Wharton School of the University of Pennsylvania, New, Annual general meeting, SPRT, PPP, India–Singapore Comprehensive Economic Cooperation Agreement, Retirement, Economics, Private Securities Litigation Reform Act, Knowledge, Harte Hanks, Plains Exploration & Production, Spice, U.S. Securities and Exchange Commission, Sale, SEC, JCP, Healthcare Facilities Accreditation Program, NYSE, ENZ, HHS, Restaurant, Company, University, Second New Deal, GLOBE, Director, NASDAQ, Goal, LLC, Vaalco Energy, Management, Security (finance), Shareholder

Under the Cooperation Agreement, the Company has agreed to promptly appoint Bradley L. Radoff as an independent member of the Board of Directors (the Board).

Key Points: 
  • Under the Cooperation Agreement, the Company has agreed to promptly appoint Bradley L. Radoff as an independent member of the Board of Directors (the Board).
  • Following the 2022 Annual Meeting, Christopher P. Mottern will retire from the Board, effective as of June 30, 2023.
  • During the term of the Cooperation Agreement, JCP and 22NW have also agreed to customary standstill provisions and voting commitments.
  • We also look forward to continuing to work with our stockholders, JCP and 22NW, going forward.

Enzo Biochem, Inc. Appoints Patricia Eckert, CPA as Interim CFO

Retrieved on: 
Thursday, October 20, 2022
CFO, Securities Act of 1933, ENZ, ASC, Efficiency, Growth, SOX, NYSE, Securities Exchange Act of 1934, BBA, MBA, Hofstra University, Pall Corporation, Company, CEO, Patent, CPA, GLOBE, Recognition, Intellectual property, Compliance, Risk, Management

NEW YORK, NY, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (Enzo or the Company), a leading biosciences and diagnostics company, today announced the appointment of Patricia Eckert, CPA, as interim Chief Financial Officer (CFO).

Key Points: 
  • NEW YORK, NY, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (Enzo or the Company), a leading biosciences and diagnostics company, today announced the appointment of Patricia Eckert, CPA, as interim Chief Financial Officer (CFO).
  • While bittersweet in light of Davids departure, we are exceedingly pleased to have Patricia in position to advance into the position of interim CFO, remarked Hamid Erfanian, CEO of Enzo.
  • I am very excited about this opportunity and appreciate the demonstration of support by Enzos executive management team and board of directors, said Patricia Eckert, interim CFO.
  • Underpinning Enzo Biochems products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Friday, October 14, 2022
Conference, STI, Hepatitis, FX, Chlamydia, CEO, Operating cost, Public expenditure, DNA, Syphilis, CDC, Biochemistry, New York State Department of Health, Severe acute respiratory syndrome coronavirus 2, DOH, NYSE, Jefferies Group, General counsel, GAAP, Investment, SG, NEW, Center, Company, Industry, Conference call, GLOBE, HPV, FDA, APOE, Growth, Review, COVID-19 testing, Laboratory, Income, EUA, Simplex, Goal, ECL, EBITDA, Internet, Rheumatology, EDX, ENZ, Total, GMP, LDT, Monkeypox, Health, Â, Research, Gonorrhea, ELS, COVID-19, Pharmaceutical industry, Management, Video game, Fine chemical, Vaccine, Reinsurance, Fossil fuel, Enzo, COVID

Enzo Life Sciences fiscal 2022 revenues amounted to $32.6 million, up 6% from fiscal 2021, or 8% on an FX adjusted basis.

Key Points: 
  • Enzo Life Sciences fiscal 2022 revenues amounted to $32.6 million, up 6% from fiscal 2021, or 8% on an FX adjusted basis.
  • Total fourth quarter 2022 revenues were $20.3 million, compared to $24.8 million in the fourth quarter 2021.
  • Consolidated gross margins were 21.4% in the fiscal fourth quarter as compared to 39.5% for the comparable quarter in the previous fiscal year.
  • Enzo Clinical Lab revenue was $12.4 million in the fiscal fourth quarter as compared to $16.8 million in the fourth quarter of 2021.

Enzo Biochem, Inc. Opens Expanded Life Sciences Laboratory and Office Facilities in Farmingdale, New York

Retrieved on: 
Thursday, October 6, 2022
Fund, ENZ, Drug Quality and Security Act, Empire State Development Corporation, Growth, NYSE, Securities Exchange Act of 1934, COO, Suffolk, Drug development, Research, Hospital Insurance and Diagnostic Services Act, Program, Risk, Securities Act of 1933, Local government, Company, CEO, Health, Outline, University, Patent, ESD, GLOBE, Intellectual property, Leadership, Pharmaceutical industry, Renewable energy, New York State Assembly

New York, NY, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the official launch of the Company’s new 100,000 square foot state-of-the-art laboratory and research facilities in Farmingdale, New York. The launch event being held this morning at 11:00 AM ET at the new Enzo headquarters will feature an outline of the Company’s plans for growth in many new areas of diagnostics, life sciences, and clinical laboratory service, and will include comments regarding the business community on Long Island from New York dignitaries. 

Key Points: 
  • Enzo Biochem is a global healthcare company that offers a range of products and services to support medical research and life sciences drug development as well as clinical diagnostic services.
  • With the opening of the companys new facilities in Farmingdale, Enzo has expanded its manufacturing operations while increasing job opportunities at its Long Island based facility.
  • It is also a confirmation of our continued commitment to the business community here on Long Island, said Hamid Erfanian, CEO of Enzo Biochem.
  • The program also includes a tour of the new laboratory facilities highlighting some of the most advanced technologies available today in clinical laboratory operations and diagnostic services.

Enzo Biochem, Inc. Launches AMPIVIEW™ Gene Expression Platform with First Products Targeting Detection of HPV and SARS-CoV-2

Retrieved on: 
Monday, September 26, 2022
Securities Exchange Act of 1934, Risk, Marie Cassidy, Woman, NYSE, Energy Independence and Security Act of 2007, World, World Health Organization, Gene, Company, Intellectual property, Securities Act of 1933, Cervical cancer, Cancer, CEO, Technology, Enzo, In situ hybridization, HPV, WHO, RNA, ENZ, GLOBE, Drug discovery, Patent, Disease, CAGR, Medical imaging

The AMPIVIEW platform with its first products for HPV detection and analysis significantly expands Enzos position in the oncology market and paves the way for expansion into the growing spatial biology space.

Key Points: 
  • The AMPIVIEW platform with its first products for HPV detection and analysis significantly expands Enzos position in the oncology market and paves the way for expansion into the growing spatial biology space.
  • Enzos AMPIVIEW RNA products combine the precision of targeted, sequence-specific probes with the superior sensitivity of its novel LoopRNA ISH technology.
  • This innovative design enables sensitive and specific detection of target genes in tissue or cell samples while preserving the morphology.
  • In HPV testing, detecting the spatial localization of active HPV in tumor cells is critical in assessing its clinical significance, and the AMPIVIEW HPV RNA probes make this possible.

Enzo Biochem to Launch Monkeypox Testing Services this Week

Retrieved on: 
Thursday, August 11, 2022
FDA, Intellectual property, Monkeypox, Personal Data Privacy and Security Act of 2009, MPX, Smallpox, Industry, NYSE, GLOBE, Population, Fluid mechanics, Securities Exchange Act of 1934, Incidence, Patent, CDC, DNA, Company, Family, ENZ, Risk, Virus, Securities Act of 1933, Monkeypox virus, Fomite, Orthopoxvirus, Vaccine

NEW YORK, NY, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (Enzo or the Company), a leading biosciences and diagnostics company, announced today that its full-service clinical laboratory will begin accepting specimens for monkeypox (MPX) testing this week.

Key Points: 
  • NEW YORK, NY, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (Enzo or the Company), a leading biosciences and diagnostics company, announced today that its full-service clinical laboratory will begin accepting specimens for monkeypox (MPX) testing this week.
  • Mr. Hamid Erfanian, Chief Executive Officer of Enzo, stated, As a leader in testing services for many viral pathogens, Enzos clinical labs understands and supports the public health issues posed by monkeypox.
  • Enzo is concurrently applying its technical expertise in molecular diagnostics to develop a next generation monkeypox (orthopoxvirus) testing option.
  • Enzo continues to meet the needs of our clients in their efforts to provide comprehensive diagnostic testing solutions for emerging pathogens.

Enzo Biochem Appoints Matthew Kupferberg as General Counsel

Retrieved on: 
Wednesday, August 3, 2022
Assistant General Counsel of the Navy (Research, Development and Acquisitions), Securities Act of 1933, Binghamton University, Securities Exchange Act of 1934, Health, DaVita Inc., NYSE, General counsel, PBM, Risk, Biotechnology, Humana, State, GLOBE, McDermott, ENZ, LLC, Phi Beta Kappa, Inc., Privacy, Intellectual property, Company, Boston College Law School, Compliance, Patent, Assistant, McDermott Will & Emery, Management, Enzo

NEW YORK, NY, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (Enzo or the Company), a leading biosciences and diagnostics company, today announced the addition of Matthew Kupferberg as the Companys in-house General Counsel.

Key Points: 
  • NEW YORK, NY, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (Enzo or the Company), a leading biosciences and diagnostics company, today announced the addition of Matthew Kupferberg as the Companys in-house General Counsel.
  • Mr. Kupferberg brings a plethora of experiences including leading transactional and legal activities for health and wellness companies and providing counsel regarding corporate governance issues.
  • Matthew Kupferberg was most recently General Counsel, Chief Compliance Officer and Privacy Officer of Digital Medical Technologies, LLC (dba AdhereTech), a medication adherence technology company.
  • He also served as Assistant General Counsel at Humana, Inc., a managed health care company that markets and administers health insurance.

6G Communications Market to 2043: Look at Low Loss and Thermal Materials

Retrieved on: 
Monday, July 25, 2022
Zero, Acquisition, RIS, Mathematics, Chapter Five, Water, Gaps, Reading, Chapter Eight, Infogram, Introduction, Executive, ENZ, Research, Radiative cooling, Sulfide, Partnership, Solution, Conclusion, Hercules, Bias, Nature, Chapter Three, Chapter Four, Terahertz, Internet, Table, IOT, Chapter Six, Invention, Lithium, Coal, Risk management, Aluminium, Printed circuit board, Fused quartz

DUBLIN, July 25, 2022 /PRNewswire/ --The "6G Communications: Low Loss and Thermal Materials Markets 2023-2043" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 25, 2022 /PRNewswire/ --The "6G Communications: Low Loss and Thermal Materials Markets 2023-2043" report has been added to ResearchAndMarkets.com's offering.
  • This report finds this is possible from low loss and thermal materials and assemblies for 6G Communications which bursts on the scene in 2030.
  • It starts at 0.1-0.3THz with incrementally-improved low loss and thermal materials in a very different mix from that for 5G.
  • Only the report, "6G Communications: Low Loss and Thermal Materials Markets 2023-2043" assesses it all
    New low loss and thermal requirements brought by 6G?

Global 6G Communications: Low Loss and Thermal Materials Market Report to 2043 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 25, 2022
Technology, Networks, Telecommunications, ENZ, IOT, View, Mathematics, Meta, Internet, Bias, Gaps, Reading, Invention, Lithium, Coal, Risk management, Borosilicate glass

The "6G Communications: Low Loss and Thermal Materials Markets 2023-2043" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "6G Communications: Low Loss and Thermal Materials Markets 2023-2043" report has been added to ResearchAndMarkets.com's offering.
  • This report finds this is possible from low loss and thermal materials and assemblies for 6G Communications which bursts on the scene in 2030.
  • It starts at 0.1-0.3THz with incrementally-improved low loss and thermal materials in a very different mix from that for 5G.
  • Wild cards for 6G thermal management: thermal metamaterial, thermal hydrogel, thermoelectric heat pump
    7.3 Thermal metamaterials for 6G devices, infrastructure and photovoltaics
    7.6 Nano Meta technologies Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005565/en/

Enzo Biochem Reports Third Quarter Fiscal 2022 Results and Provides Leadership and Corporate Updates Including Engagement of Jefferies as Financial Advisor

Retrieved on: 
Thursday, June 9, 2022
SRL Diagnostics, Internet, CFO, Company, Conference, Conference call, EBITDA, COO, Eastern Time Zone, Income, Corporation, Quality, Annual general meeting, FX, COVID-19 testing, ELS, Senior, ENZ, Investment, Quality assurance, Regulatory affairs, FDA, Growth, GLOBE, LDT, Review, NYSE, Trichomonas, GAAP, COVID-19, ISO 9000, Compliance, Research, Depreciation, Gonorrhea, NEW, Jefferies Group, HPV, Certification, New York State Department of Health, Efficiency, Chlamydia, Calendar, Vaccine, Fine chemical, Bank, Pharmaceutical industry, Q3

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc (NYSE: ENZ), a leading biosciences and diagnostics company, today reported financial results for the third fiscal quarter ended April 30, 2022, and provided a business update on recent corporate and operational developments.

Key Points: 
  • In April 2022, the Company announced the approval of all four proposals presented at the 2022 Annual Meeting of Shareholders.
  • These modifications improve the Companys corporate governance and allow the newly formed leadership team to further prioritize shareholder-friendly initiatives.
  • Enzo Clinical Lab revenues totaled $18.6 million in the third quarter, a decrease of 26% from $25.0 million in the third quarter of fiscal 2021.
  • The Company will host a conference call on Friday, June 10, 2022, at 8:30 am, Eastern Time, to review the operational, corporate, and financial highlights.